If approved, Mavenclad could offer a more patient-friendly ... EUSA Pharma gets another cancer drug recommended And EUSA Pharma, an up-and-coming niche player in cancer, saw its Fotivda (tivozanib ...
Mavenclad (cladribine ... that Merck is counting on to maintain its recovery after a difficult 2018 is cancer immunotherapy Bavencio (avelumab). The drug grew 52.5% to €29 million in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback